Let’s Discuss Your Development Program Needs
Whether you are planning a preclinical strategy, preparing for IND-enabling studies, evaluating regulatory expectations, or seeking experienced nonclinical, clinical, or regulatory guidance for global drug development, SGI Consulting can help you determine the right next step.
Led by Christopher W. Stewart, PhD, DABT, SGI Consulting works with Sponsors worldwide to support nonclinical program design, translational toxicology interpretation, regulatory communications, submissions, training, and coordination with trusted subject matter experts.
If you are preparing for drug entry into the U.S., Asia, or European markets, or need experienced perspective on a complex development question, we invite you to reach out.
